Ethanol Tolerance Affects Endogenous Adenosine Signaling in Mouse Hippocampus

Dali Zhang, Wei Xiong, Michael F. Jackson, and Fiona E. Parkinson

Department of Pharmacology and Therapeutics, University of Manitoba, and Neuroscience Research Program, Health Sciences Centre, Winnipeg, Manitoba, Canada

Received January 20, 2016; accepted April 18, 2016

ABSTRACT

Ethanol has many pharmacological effects, including increases in endogenous adenosine levels and adenosine receptor activity in brain. Ethanol consumption is associated with both positive and negative health outcomes, but tolerance to the behavioral effects of ethanol can lead to increased consumption, which increases the risk of negative health outcomes. The present study was performed to test whether a 7-day treatment with ethanol is linked to reduced adenosine signaling and whether this is a consequence of reduced ecto-5'-nucleotidase activity. Wild-type (CD73+/+) and ecto-5'-nucleotidase-deficient (CD73−/−) mice were treated with ethanol (2 g/kg) or saline for 7 days. In CD73+/+ mice, repeated ethanol treatment reduced the hypothermic and ataxic effects of acute ethanol, indicating the development of tolerance to the acute effects of ethanol. In CD73−/− mice, this 7-day ethanol treatment led to increased hippocampal synaptic activity and reduced adenosine A<sub>1</sub> receptor activity under both basal and low Mg<sup>2+</sup> conditions. These effects of ethanol tolerance were associated with an 18% decrease in activity of ecto-5'-nucleotidase activity in hippocampal cell membranes. In contrast, ethanol treatment was not associated with changes in synaptic activity or adenosine signaling in hippocampus from CD73−/− mice. These data indicate that ethanol treatment is associated with a reduction in adenosine signaling through adenosine A<sub>1</sub> receptors in hippocampus, mediated, at least in part, via reduced ecto-5'-nucleotidase activity.

Introduction

Ethanol is widely consumed in many countries and has both positive and negative social, economic, and health consequences. In general, the negative outcomes are associated with high levels of consumption and include alcohol use disorders. One factor that can lead individuals to consume increasing quantities of ethanol is tolerance to its effects. The acute effects of ethanol in humans include euphoria, social stimulation, anxiolysis, drowsiness, slurred speech, ataxia, and impulsivity (Heinz, et al., 2011). Frequent consumption of ethanol produces functional tolerance, such that a user requires greater quantities of ethanol to produce these effects. Ethanol’s effects are primarily attributed to facilitation of the inhibitory neurotransmitter GABA and inhibition of the excitatory neurotransmitter glutamate (Harris, et al., 2008). However, adenosine also contributes to the acute pharmacological effects of ethanol; in particular, the ataxia and sleep induced by ethanol are attenuated by adenosine A<sub>1</sub>R receptor antagonists (Dar, 1990, 2001; Thakkar, et al., 2010; Sharma, et al., 2014).

Ethanol enhances adenosine levels in brain (Sharma, et al., 2010b). Two mechanisms have been identified by which ethanol increases both adenosine levels and adenosine receptor activity. First, ethanol inhibits an adenosine transporter, equilibrative nucleoside transporter 1 (ENT1) that transfers adenosine across cell membranes in a direction dictated by its concentration gradient (Nagy, et al., 1990; Allen-Gipson, et al., 2009; Kim, et al., 2011). Second, the ethanol metabolite acetate produces central nervous system (CNS) effects that are blocked by adenosine receptor antagonists (Carmichael, et al., 1991; Cullen and Carlen, 1992), and it has been proposed that metabolism of acetate to acetyl CoA produces AMP, which is further metabolized to adenosine (Carmichael, et al., 1993).

Adenosine exerts a basal inhibitory “tone” in CNS as evidenced in vivo by the adenosine receptor antagonist caffeine, a psychostimulant consumed by 80% of the world’s population to increase alertness (Lara, 2010). This inhibitory adenosine tone can also be readily demonstrated in vitro; application of an adenosine A<sub>1</sub> receptor antagonist reverses this inhibition and facilitates glutamatergic synaptic transmission. Extracellular adenosine levels are regulated, in part, by a cascade of ecto-enzymes that metabolizes extracellular adenine nucleotides (ATP, cAMP) to adenosine. Ecto-5’-nucleotidase forms adenosine from AMP and is the final enzyme in the cascade. This protein is also known as CD73, whereas the gene is termed 5NTE or NT5E (Zimmermann, et al., 2012).

Whereas adenosine is known to contribute to the acute effects of ethanol, adenosine levels are reduced following chronic ethanol exposure and contribute to the insomnia and seizures

ABBREVIATIONS: aCSF, artificial cerebral spinal fluid; AOPCP, α,β-methylene adenosine diphosphate; BAC, blood alcohol concentration; CNS, central nervous system; CPA, N<sub>6</sub>-cyclopentyladenosine; DMSO, dimethylsulfoxide; DPCPX, 8-cyclopentyl-1,3-dipropyl-xanthine; ENT1, equilibrative nucleoside transporter 1; fEPSP, field excitatory postsynaptic potential; PPF, paired-pulse facilitation; RT-PCR, reverse-transcription polymerase chain reaction.
associated with ethanol withdrawal (Sharma, et al., 2010a; Kim, et al., 2011). Thus, functional tolerance to ethanol may be mediated, in part, by changes in the regulation of endogenous adenosine. The present study made use of a 7-day ethanol treatment protocol and examined the effect of this treatment on synaptic activity and ecto-5′-nucleotidase activity in hippocampus.

Materials and Methods

Ethanol Treatment of Mice. Male CD73+/− and CD73−/− mice (C57Bl6) were housed in a dedicated mouse facility at three to four per cage, with ad libitum access to food and water, and a light/dark cycle of 12:12 with lights on at 0600. Treatments were initiated when mice were 7–8 weeks of age. Ethanol was prepared as a 20% solution in saline. Mice were given intraperitoneal injections of ethanol (2 g/kg) or an equivalent volume of saline. Mice were given a single injection of ethanol or injections of ethanol or saline every 24 hours for 7 days.

All procedures with animals were in accordance with guidelines set by the Canadian Council on Animal Care and approved by the University of Manitoba Animal Protocol Management and Review Committee. CD73+/− mice were obtained from Dr. Linda Thompson (Thompson, et al., 2004) and bred locally. Previously, we reported the absence of ecto-5′-nucleotidase activity in brain samples and cultured astrocytes from these mice (Zhang, et al., 2012; Chu, et al., 2014).

Hypothermic Response to Ethanol. Mice were familiarized with the procedure of determining body temperature by insertion of a rectal thermometer probe. On each of the three days before ethanol injection, each mouse was handled gently and given light anesthesia. The light anesthesia was used to reduce agitation. The probe of a digital thermometer was inserted 1.5 cm into the rectum and left in place for approximately 10 seconds until the temperature reading was stable. After ethanol treatment, mice were docile and no anesthesia was used. Body temperature was recorded at 30 and 120 minutes after the first and the seventh ethanol injection.

Ataxic Response to Ethanol. Mice, 7–8 weeks of age, were trained over 3 days to run on a rotarod for 180 seconds at 20 rpm (Dar, 1997; Parkinson, et al., 2009). All mice were successfully trained to perform this task. Mice were then injected (intraperitoneally) with 2 g/kg ethanol and placed on the rotarod immediately and again every 15 minutes for 60 minutes. Beginning the following day, mice were injected once per day for an additional 6 days with ethanol. Immediately after the final (seventh) ethanol injection, mice were retested on the rotarod. The amount of time each mouse remained on the rotarod to a maximum of 180 seconds was measured.

Blood Alcohol Concentration. Blood samples were collected from the saphenous vein 30 and 120 minutes after a single ethanol injection or after the last of seven (one per day) ethanol injections. Blood alcohol concentration (BAC) was determined using an Analox GM7 analyzer (Analox Instruments, London, United Kingdom) following the manufacturer’s protocol.

Hippocampal Slice Preparation. All hippocampal slice recordings were obtained from mice euthanized 24 hours after the last ethanol or saline injection. Mice were anesthetized with isoﬂurane and decapitated. Each brain was rapidly removed and placed in ice-cold oxygenated (95% O2/5% CO2) artificial cerebrospinal fluid (aCSF) of the following composition (mM): 124 NaCl, 3.0 KCl, 1.2 MgCl2, 2.0 CaCl2, 1.25 KH2PO4, 26 NaHCO3, 10 d-glucose, pH 7.4, adjusted to 285–290 mOsM. Hippocampus was removed and 350–μm slices were cut using a McIlwain Tissue Chopper (Stoelting Co., Wood Dale, IL). The slices were then allowed to recover in a holding chamber for at least 1 hour at 32.5°C prior to electrophysiological recording.

Extracellular Recordings. Individual slices were transferred to a submerged recording chamber (Harvard Apparatus, Holliston, MA) and continuously superfused with oxygenated aCSF at a flow rate of 1.5 ml/min (32.5°C). Each slice was placed on a suspended nylon net to allow perfusion and oxygenation of the slice from above and below. Synaptic responses were evoked by stimulation of the Schaffer collateral/commissural pathway with a concentric bipolar stimulating electrode with 0.1-millisecond pulse width at 30-second intervals. Extracellular field excitatory post synaptic potentials (fEPSPs) were recorded in stratum radiatum of CA1 hippocampus using glass microelectrodes (1–2 Ω) filled with aCSF. Input/output curves were obtained by gradual increases in stimulus voltage. The baseline recording was established at 40–50% maximal fEPSP response. At least 15–20 minutes of stable baseline was obtained in each experiment. To study paired-pulse facilitation (PPF), synaptic responses were evoked by two stimuli with 50-millisecond interpulse interval. To assess basal adenosine tone, the stimulatory effect of the adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 1 μM) was compared in slices from saline-treated and ethanol-treated mice. To assess the effect of ethanol treatment on epileptiform-bursting synaptic activity, slices were transferred to the recording chamber and superfused with Mg2+-free aCSF for 20 minutes. The frequency of spontaneous epileptiform events was then monitored for 5 minutes. To determine whether basal adenosine levels suppress epileptiform activity the same in slices from saline-treated and ethanol-treated mice, the superfusion solution was then switched to Mg2+-free aCSF containing DPCPX (1 μM). Spontaneous epileptiform activity was determined for an additional 20 minutes. Data were collected using an Axopatch 1D amplifier and analyzed using pCLAMP 10 software (Molecular Devices, Sunnyvale, CA).

To examine for changes in A1 receptor function, slices from saline-treated and ethanol-treated mice were superfused with graded concentrations of adenosine (10–50 μM) or N6-cyclopentyladenosine (CPA; 1 nM–1 μM). The maximum inhibitory response to each concentration was used to perform nonlinear regression analysis and obtain estimates of IC50 values.

Quantitative Reverse-Transcription Polymerase Chain Reaction. Hippocampal slices were collected from CD73+/− mice 24 hours after the last injection of ethanol or saline. Total RNA was isolated, reverse transcribed, and amplified using a Bio-Rad iCycler iQ Real-Time PCR Detection System as previously described (Zhang, et al., 2012). Primer sequences are provided in Table 1. Quantitative reverse-transcription polymerase chain reaction (RT-PCR) data were normalized to the corresponding β-actin values and expressed relative to gene expression in the saline-treated mice using the 2−ΔΔCT method (Livak and Schmittgen, 2001).

Ecto-5′-Nucleotidase Assays. Ecto-5′-nucleotidase assays were performed as previously described (Zhang, et al., 2012). Briefly, hippocampus was collected from saline- or ethanol-treated mice 24 hours after the last injection. Cell membrane proteins (30 μg/assay) were incubated for 15 minutes at room temperature with 10 μM [32P]AMP (0.22 Bq/pmol), with or without the ecto-5′-nucleotidase inhibitor a,b-methylene adenosine diphosphate (OAPCP; 50 μM) in a buffer containing 110 mM NaCl, 25 mM glucose, 68.3 mM sucrose, 5.3 mM KCl, 1.8 mM CaCl2, 1.0 mM MgSO4, and 20 mM HEPES (pH 7.4). Thin-layer chromatography was used to separate [32P]adenosine, [32P]inosine, and [32P]hypoxanthine, which were then quantified by scintillation spectroscopy and expressed as picomoles produced per microgram of protein.

Drugs. DPCPX, dimethylsulfoxide (DMSO), and CPA were purchased from Sigma-Aldrich Canada Ltd. (Oakville ON). Stock solutions (10 mM) of DPCPX and CPA were prepared in DMSO, then diluted to the final concentrations with aCSF. AOPCP was obtained from Tocris Bioscience (Bristol, UK).

Statistical Analysis. All numerical data are expressed as means ± S.E.M. Data were tested for statistical significance with two-tailed Student’s t test or with one-way or two-way analysis of variance (ANOVA). A value of p < 0.05 was considered statistically significant.

Results

CD73+/− mice have been used previously to address the source of adenosine formed in brain tissue and cultured cells during conditions such as hypoxia, ischemia, and neuronal
activity (Zhang, et al., 2012; Wall and Dale, 2013; Chu, et al., 2014). By using this genetic mouse model we were able to circumvent the limitations inherent in the use of pharmacological tools to provide long-term in vivo inhibition of the enzyme.

**Tolerance to the Acute Effects of Ethanol after a 7-day Treatment with Ethanol.** A well-known effect of ethanol is a reduction in body temperature. Mice given a single injection of ethanol showed a drop in body temperature; at 30 minutes postinjection body temperature was reduced 2.2 ± 0.1°C in CD73+/− mice and 2.4 ± 0.1°C in CD73−/− mice (Fig. 1A and B). This effect persisted and body temperature was still depressed by more than 1°C at 120 minutes postinjection. Mice that had received daily ethanol treatments showed a significantly reduced hypothermic effect following the seventh injection: body temperature was reduced by 1.7 ± 0.03 and 1.2 ± 0.1°C at 30 and 120 minutes postinjection, respectively, in CD73+/− mice (Fig. 1A) and 1.7 ± 0.1°C and 1.1 ± 0.2°C at 30 and 120 minutes postinjection, respectively, in CD73−/− mice (Fig. 1B). Thus, CD73+/− and CD73−/− mice showed similar body temperature responses to the first and the seventh exposure to ethanol.

Another well-known effect of ethanol is ataxia. CD73+/− and CD73−/− mice given a single injection of ethanol showed a rapid and persistent decrease in motor co-ordination, as revealed by rotarod performance (Fig. 1, C and D). At 60 minutes postinjection, CD73+/− mice showed some recovery in contrast to CD73−/− mice. CD73+/− mice that had received one injection of ethanol per day for 7 days exhibited a significantly greater ability to remain on the rotarod by 30 minutes. In contrast, in CD73−/− the start of rotarod performance recovery was delayed until 45 minutes following the last ethanol injection. Overall performance was on rotarod task was less in CD73−/− mice compared with CD73+/− mice (Figs. 1, C and D, insets). After 7 days of ethanol treatment, CD73+/− mice exhibited reduced tolerance to the behavioral effects of ethanol compared with CD73−/− mice.

**Pharmacokinetic Ethanol Tolerance Develops with a 7-Day Ethanol Treatment.** Chronic ethanol consumption can lead to altered ethanol metabolism, specifically, induction of liver microsomal enzymes, such as Cyp2E1. Enhanced ethanol metabolism can reduce the ethanol concentration in the blood and, thus, reduce the effects of ethanol. In CD73+/− mice, blood samples were taken at 30 and 120 minutes following the first and the seventh injections of ethanol. At 30 minutes postinjection blood alcohol concentrations were identical, but at 120 minutes postinjection a 21% decrease in blood alcohol concentration was observed in mice treated for 7 days, compared with mice given a single injection (Fig. 1E). Similarly, in CD73−/− mice treated for 7 days, blood alcohol concentrations at 30 minutes were unchanged but at 120 minutes were reduced by 21% in comparison with CD73−/− mice receiving a single ethanol injection (Fig. 1F).

**Ethanol Treatment Increases Basal Synaptic Activity in CD73+/− but Not CD73−/− Mice.** CD73+/− and CD73−/− mice were given saline or ethanol every 24 hours for 7 days, then hippocampal slices were prepared 24 hours after the last injection. Using fEPSP recordings, we first generated input-output curves and found an increase in basal synaptic transmission in response to stimulus intensities greater than 2.8 V in slices from ethanol-treated CD73+/− mice, compared with slices from saline-treated mice (Fig. 2A). Next, we examined PPF, in which two electrical pulses were delivered in 50 milliseconds. PPF is increased in the presence of adenosine or adenosine A1 receptor agonists and is decreased by adenosine removal or A1 receptor antagonists (Dunwiddie and Haas, 1985; Brust, et al., 2007; Chen, et al., 2014). We found reduced PPF in slices from ethanol-treated, relative to saline-treated CD73+/− mice (Fig. 2C). In contrast, input-output curves and PPF were not altered in slices from ethanol-treated, compared with saline-treated CD73−/− mice (Fig. 2, B and D).

**Ethanol Treatment Is Associated with Reduced Adenosine Tone in CD73+/− Mice.** To address whether the altered basal synaptic transmission in slices from ethanol-treated CD73+/− mice was associated with changes in basal adenosine A1 receptor activity, we used the selective adenosine A1 receptor antagonist DPCPX (1 μM). DPCPX increased fEPSP slope in slices from both ethanol-treated and saline-treated CD73+/− mice but had a significantly greater effect in slices from saline-treated mice (Fig. 2E). In contrast, DPCPX had a similar stimulatory effect in slices from both ethanol-treated and saline-treated CD73−/− mice (Fig. 2F).

Epileptiform-bursting synaptic activity was evaluated in hippocampal slices superfused with Mg2+-free aCSF before and during DPCPX application (Fig. 3). In slices from CD73+/− mice, a significant increase in bursting activity was observed in slices from ethanol-treated compared with slices from saline-treated mice (Fig. 3C). This was not observed between slices from ethanol-treated and saline-treated CD73−/− mice (Fig. 3G). Application of DPCPX (1 μM) stimulated epileptiform-bursting activity in slices from both CD73+/− and CD73−/− mice.
(Fig. 3D, H), indicating the presence of endogenous adenosine and activation of A1 receptors. Beginning 5 minutes after application of DPCPX, epileptiform-bursting was significantly greater in slices from saline-treated compared with ethanol-treated CD73+/+ mice (Fig. 3D). In contrast, no significant difference in the response to DPCPX was observed between slices from saline-treated and ethanol-treated CD73–/– mice (Fig. 3H).

Ethanol Treatment Reduced Inhibitory Responses to Adenosine, but Not the Adenosine A1 Receptor Agonist CPA, in Slices from CD73+/+ Mice. To test whether a 7-day ethanol treatment is associated with changes in the inhibitory potency of adenosine or the selective A1 receptor agonist CPA, fEPSPs were recorded from slices treated with graded concentrations of adenosine (10–50 μM) or CPA (1 nM–1 μM) (Fig. 4, A and B). The inhibitory effect of adenosine, but not CPA, showed a small reduction in slices from ethanol-treated and ethanol-treated CD73–/– mice (Fig. 3H).

For CPA, IC50 values were 22 (16–29) nM and 25 (18–35) nM for slices from saline-treated and ethanol-treated mice, respectively. Thus, adenosine but not CPA showed a small but significant difference in inhibitory potency between hippocampal slices from saline-treated and ethanol-treated CD73+/+ mice.

Ethanol Treatment Did Not Have a Significant Effect on Gene Expression of Adenosine A1 Receptors, Nucleoside Transporters, or Purinergic Enzymes in Hippocampal Tissue from CD73+/+ Mice. Quantitative RT-PCR data from hippocampus isolated from saline- and ethanol-treated CD73+/+ mice was normalized to their respective β-actin values and expressed relative to saline-treated gene expression using the 2^ΔΔCt method (Livak and Schmittgen, 2001). Ethanol treatment was not associated with statistically significant changes in gene expression of adenosine A1 receptors ENT1, ENT2, adenosine kinase, or ecto-5′-nucleotidase, although a trend (repeated-measures ANOVA, P = 0.04; no statistically significant differences were detected with Dunnet’s multiple comparison post-tests) toward reduced expression of ecto-5′-nucleotidase was noted (Fig. 5A).

Given the trend toward a decrease in expression of ecto-5′-nucleotidase, ecto-5′-nucleotidase assays were performed. An 18% decrease in ecto-5′-nucleotidase activity in hippocampus from ethanol-treated, relative to saline-treated, mice was
observed (Fig. 5B). Specificity of the assay was verified by the 78–82% inhibition of adenosine formation in the presence of AOPCP, an inhibitor of ecto-5'-nucleotidase, and the low levels of inosine and hypoxanthine produced.

**Discussion**

The main findings of this study were that treatment with ethanol (2 g/kg per day, i.p.) for 7 days was associated with a degree of tolerance to the acute hypothermic and ataxic effects of ethanol in both CD73+/+ and CD73−/− mice, whereas increased basal synaptic activity and reduced basal inhibitory adenosine tone were observed in hippocampus of CD73+/+ mice but not in CD73−/− mice. This evidence for an important role of ecto-5'-nucleotidase was supported by the observation that ecto-5'-nucleotidase activity was significantly reduced in hippocampus isolated from CD73+/+ mice treated with ethanol.

Although low levels of ethanol consumption are associated with health benefits, high levels of consumption are associated with adverse health outcomes, including cancers, liver damage, and alcohol use disorders. Chronic use of ethanol is associated with both functional and pharmacokinetic tolerance. Increasing levels of tolerance to the effects of ethanol can lead to further increases in ethanol consumption and, therefore, increased risk of adverse health outcomes. Addressing the mechanisms that underlie tolerance could, in principle, slow or prevent dose escalation and reduce the risk of ethanol-linked health concerns. As some reports indicate that reduced adenosine signaling is involved in alcohol withdrawal and relapse (Sharma, et al., 2010a; Kim, et al., 2011), the present study was undertaken to address whether a 7-day ethanol treatment is associated with altered adenosine signaling.

Many animal models have been developed for studies of alcohol use disorders (Plackett and Kovacs, 2008; Knapp and Breese, 2012). In the present study, ethanol was administered to mice by intraperitoneal injection. This was to ensure that all animals received the same dose, had reproducible profiles of blood alcohol levels, and blood alcohol levels dropped to zero between doses. The peak blood levels measured were about 42 mM, or 180 mg/dl (180 mg%), which, depending on
jurisdiction, exceeds by 2- to 3-fold the legal level allowed for a human operating a motor vehicle. Thus, the profile of blood alcohol levels in the present study shows a general similarity to binge drinking, a risk factor for alcohol use disorders and alcohol-linked adverse health outcomes in humans (Crabbe, et al., 2011).

In this study, all animals exhibited hypothermic and ataxic responses to ethanol, with a modest level of tolerance evident after 7 days of ethanol treatment. In principle, increased ethanol metabolism, by reducing blood alcohol levels, could reduce responses to acute ethanol. A degree of pharmacokinetic tolerance was observed; however, peak plasma levels determined 30 minutes postinjection were not significantly different between mice receiving their first or their seventh ethanol injection. Therefore, the observed tolerance to the hypothermic and ataxic effects of ethanol, observed with Mg²⁺-free aCSF for 5 minutes then with Mg²⁺-free aCSF containing DPCPX (1 μM) for an additional 20 minutes, and epileptiform-bursting activity was recorded. Representative traces are shown from individual slices from saline-treated CD73+/+ (A) and CD73−/− (E) mice and from ethanol-treated CD73+/+ (B) and CD73−/− (F) mice. The boxed regions are expanded as indicated and represent 1-minute intervals before and during DPCPX application. (C, G) fEPSPs were counted for 5 minutes and reported as events per second (Hz), and a significant increase in epileptiform-bursting was observed only in slices from ethanol-treated CD73+/+ mice. (D, H) After the addition of DPCPX, fEPSPs were counted, in 5-minute bins, for an additional 20 minutes. DPCPX produced a greater stimulation of epileptiform-bursting in saline-treated than in ethanol-treated slices from CD73+/+ mice. n = 5 (C, D) or 4 (G, H). *P < 0.05 for two-tailed t test (C); *P < 0.05; ***P < 0.001 for saline versus ethanol treatment; two-way ANOVA (D).

Endogenous adenosine, acting at A₁ receptors in hippocampal slices, reduces glutamatergic excitatory synaptic transmission, resulting in reduced input-output relations, increased PPF, and suppressed epileptiform-bursting (Dunwiddie and Haas, 1985; Brust, et al., 2007; Etherington, et al., 2009; Chen, et al., 2014). In slices from CD73+/+ mice, ethanol treatment was associated with an increased input-output relationship, a decreased PPF, an increase in epileptiform-bursting, and an attenuated excitatory effect of DPCPX, indicating a reduced level of endogenous adenosine and reduced basal activation of A₁ receptors in CD73+/+ mice treated for 7 days with ethanol.

Increased excitability and a link to reduced basal adenosine tone was observed in CD73−/− but not in CD73−/− mice. Previously, we reported that in this strain of CD73−/− mice
other mechanisms such as tissue nonspecific alkaline phosphatase appear to compensate, in part, for the loss of ecto-5'-nucleotidase (Zhang, et al., 2012), and this may explain why adenosine tone in slices stimulated at a very low rate (0.033 Hz) was not reduced in slices from CD73\(^{-/-}\) mice (see Fig. 2F). Interestingly, in an independent strain of CD73\(^{-/-}\) mice, a change in tissue-nonspecific alkaline phosphatase was not observed (Langer, et al., 2008). A low Mg\(^{2+}\) buffer increased neuronal activity to 0.2 Hz in slices from both saline-treated and ethanol-treated CD73\(^{+/+}\) and CD73\(^{-/-}\) mice (see Fig. 3, C and G). As the stimulatory effect of DPCPX, a measure of adenosine levels, was greater in slices from saline-treated CD73\(^{+/+}\) mice than in slices from saline-treated CD73\(^{-/-}\) mice, ecto-5'-nucleotidase appears to be important for the formation of endogenous adenosine in this condition of high neuronal activity, even if other mechanisms can compensate for its absence at low levels of activity. As revealed by DPCPX, the production of adenosine by low Mg\(^{2+}\)-induced neuronal activity was attenuated in slices from ethanol-treated CD73\(^{+/+}\) and was similar to that observed in low Mg\(^{2+}\)-treated slices from saline-treated and ethanol-treated CD73\(^{-/-}\) mice (see Fig. 3, D and H).

In hippocampal slice preparations from ethanol-treated CD73\(^{+/+}\) mice, we observed a small reduction in the inhibitory effect of exogenous adenosine. The net response is attributable to the exogenous plus endogenous adenosine and, thus, is reduced as a direct result of the reduced contribution of endogenous adenosine in slices from ethanol-treated, compared with saline-treated, CD73\(^{+/+}\) mice. This reduced inhibitory effect of adenosine and reduced adenosine tone in slices from ethanol-treated CD73\(^{+/+}\) mice could be explained by reduced adenosine formation, reduced adenosine A1 receptor activity, or increased adenosine clearance. However, ethanol treatment did not affect the responses to the exogenous A1 receptor agonist CPA and did not affect gene expression of adenosine A1 receptors, indicating that these receptors are not regulated in this model of ethanol tolerance. Adenosine influx mediated by ENT1 and/or ENT2 and intracellular metabolism by adenosine kinase in astrocytes constitutes the predominant clearance pathway for adenosine in CNS (Boison, 2012). Gene expression of these transporters and this enzyme was also not affected in ethanol tolerance.

A trend toward a reduction in expression of ecto-5'-nucleotidase and a significant decrease in ecto-5'-nucleotidase activity was observed in hippocampal tissue from ethanol-treated CD73\(^{+/+}\) mice. This, together with the absence of an effect of ethanol treatment on adenosine levels in hippocampal

![Fig. 4. Inhibition by adenosine or CPA of fEPSP recordings in hippocampal slices from mice injected (intraperitoneal) with saline or ethanol (2 g/kg) every 24 hours for 7 days. Hippocampal slice recordings were obtained 24 hours after the last injection. Graded concentrations of adenosine or CPA were superfused as indicated by the horizontal lines. Representative traces at the times indicated are illustrated. Calibration bars correspond to 0.5 mV and 10 milliseconds. n = 10 (A) or 5 (B). *P < 0.05, two-tailed t test.](image)

![Fig. 5. Relative expression of purinergic genes and activity of ecto-5'-nucleotidase. CD73\(^{-/-}\) mice were treated with saline or ethanol (2 g/kg, i.p.) every 24 hours for 7 days. Hippocampus was collected 24 hours after the last injection. (A) Total RNA was isolated and used for quantitative RT-PCR. Expression of adenosine A1 receptors (A1R), adenosine kinase (AK), equilibrative nucleoside transporters 1 and 2 and ecto-5'-nucleotidase (eN) was determined. Gene expression was normalized to actin and expression in ethanol-treated, relative to saline-treated samples is shown. Data were analyzed by repeated measures ANOVA (P = 0.04) with Dunnet’s multiple comparison post tests. (B) Hippocampal cell membranes were isolated and incubated with \(^{[14]C}\)AMP in the presence of absence of AOPCP (50 \(\mu\)M) and the formation of \(^{[14]C}\)labeled adenosine (ADO), inosine (INO), and hypoxanthine (HX) was quantified. \(*P < 0.01, ***P < 0.001, relative to saline-treated; \#\#\#P < 0.001, relative to ethanol-treated; one way ANOVA with Bonferroni post-tests. n = 5 (A) or 6 (B).](image)
tissue from CD73−/− mice, indicates that regulation of ecto-5′-nucleotidase plays an important role in the attenuation of adenosinergic mechanisms that is associated with repeated ethanol exposure. Further studies are required to investigate the mechanisms by which ethanol treatment reduces ecto-5′-nucleotidase activity.

In summary, whereas ethanol has multiple pharmacological targets and several mechanisms that contribute to ethanol tolerance, this study has demonstrated that 7 days of repeated ethanol treatment attenuated the increases in adenosine that are induced by neuronal activity. Specifically, in hippocampus both isolated ecto-5′-nucleotidase activity and ecto-5′-nucleotidase activity associated with neuronal excitation were reduced following 7 days of ethanol exposure. Of note, as tolerance to hypothermic effects of ethanol were similar in CD73−/− and CD73+/+ mice, altered ecto-5′-nucleotidase activity contributes to some but not all signs of ethanol tolerance. Elucidation of the specific mechanisms that underlie ethanol-induced changes, and comparison of these changes in different brain regions and cell types, may reveal strategies to mitigate or treat ethanol tolerance.

Authorship Contributions

Participated in research design: Parkinson, Zhang, Jackson, Xiong. Conducted experiments: Zhang, Xiong. Performed data analysis: Parkinson, Zhang, Xiong. Wrote or contributed to the writing of the manuscript: Parkinson, Jackson.

References


Address correspondence to: Dr. Fiona E. Parkinson, SR440-710 William Avenue, Winnipeg MB Canada R3E 0Z3. E-mail: Fiona.Parkinson@umanitoba.ca.